https://dinamiqs.com/  

8952 Schlieren, Wagistrasse 25

 info@dinamiqs.com

We are a science-driven contract development and manufacturing organization offering end-to-end viral vector manufacturing solutions. We offer customized services for companies and institutions developing innovative genetic medicines. As a science and technology-driven platform, we provide a comprehensive approach to viral vector manufacturing, from lab-scale development to scalable bioreactor implementation, process optimization, formulation, and stringent quality control.

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

http://www.neurimmune.com  

8952 Schlieren, Wagistrasse 18

 +41 44 755 46 46
 info@neurimmune.com

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.

http://www.molecularpartners.com  

8952 Schlieren, Wagistrasse 14

 +41 44 755 77 00

Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.

http://virometix.com  

8952 Schlieren, Wagistrasse 14

 +41 (0)43 433 86 60
 info@virometix.com

Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.

http://www.dualsystems.com  

8952 Schlieren, Grabenstrasse 11a

 +41 44 738 50 00
 info@dualsystems.com

Dualsystems Biotech is a provider of proteomics services for industry and academia.

https://kowapharmaceuticals.eu/  

8952 Schlieren, Zürcherstrasse 39D

Kowa Pharmaceutical Europe Co. Ltd. is a specialty pharmaceutical company located in the UK and is a division of Kowa Company, Ltd., a multinational Japanese company actively engaged in a broad variety of manufacturing and trading activities. Kowa are committed to improving health standards in Europe and globally.

https://kuori.ch/  

8952 Schlieren, Wagistrasse 4

 info@kuori.ch

We started KUORI in 2022. We are an innovative Swiss Cleantech company committed to transitioning to a post-oil economy by transforming consumer plastics through a circular economy approach. As a B2B enterprise, we provide cutting-edge and eco-friendly granules, seamlessly fitting into existing manufacturing processes of diverse sectors including fashion, outdoor equipment and tools. Overall our material has a PCF (Product Carbon Footprint) potentially 60% lower compared to conventional plastics. We leverage food byproducts - such as olive pits and walnut shells - to produce novel bio-based, biodegradable, and elastic materials that have a patent pending. Our materials only produce biodegradable microplastics, directly addressing a critical environmental concern.